Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
Open Access
- 24 August 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pituitary
- Vol. 15 (3), 398-404
- https://doi.org/10.1007/s11102-011-0335-y
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Significant tumour shrinkage after 12 months of lanreotide Autogel‐120 mg treatment given first‐line in acromegalyClinical Endocrinology, 2009
- Somatostatin agonists for treatment of acromegalyMolecular and Cellular Endocrinology, 2007
- A 12‐month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long‐acting repeatable on GH and IGF‐l in patients with acromegalyClinical Endocrinology, 2007
- The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenomaClinical Endocrinology, 2007
- Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patientsPituitary, 2007
- Efficacy of a slow‐release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal studyClinical Endocrinology, 2007
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- Long‐term (up to 18 years) effects on GH/IGF‐1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH‐secreting pituitary adenoma responsive to SSTaClinical Endocrinology, 2007
- Slow release lanreotide treatment in acromegalic patients previously normalized by octreotideJournal of Clinical Endocrinology & Metabolism, 1994
- AcromegalyNew England Journal of Medicine, 1990